{
  "ticker": "RHY",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970041",
  "id": "02970041",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250717",
  "time": "0847",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lw5ncxggdwls.pdf",
  "summary": "### Summary of Material Information:  \n- **Strategic Pilot Program**: First domestic pilot partnership for geneTypeTM since acquisition.  \n- **Commercial Pathway**: Key step in expanding domestic commercialization of geneTypeTM, with potential for future revenue growth.  \n- **Execution**: Pilot to commence in Victoria with dedicated resources from both Rhythm Biosciences and the unnamed pathology provider.  \n\n*No capital markets or trading-specific actions (e.g., raising, halt, material financials) identified.*",
  "usage": {
    "prompt_tokens": 1189,
    "completion_tokens": 96,
    "total_tokens": 1285,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T22:58:28.237075"
}